Pharmacological inhibition of mitochondrial membrane permeabilization for neuroprotection

Experimental Neurology

Volumn 218, Issue 2, 2009, Pages 347-352

  Hisatomi, Toshio ^a,b   Ishibashi, Tatsuro ^a   Miller, Joan W ^b   Kroemer, Guido ^c,d,e  

^a KYUSHU UNIVERSITY   (Japan)

^b MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^c INSERM   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

AIF; Apaf 1; Apoptosis; Caspase; Cytochrome c; Mitochondria membrane permeabilization; Retina

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1 INHIBITOR; CASPASE 9; CYCLOPHILIN D; CYCLOSPORIN A; CYTOCHROME C; MATRIX METALLOPROTEINASE INHIBITOR; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; MITOCHONDRIAL PERMEABILITY TRANSITION PORE INHIBITOR; NEUROPROTECTIVE AGENT; PEPTIDOMIMETIC AGENT; PIGMENT EPITHELIUM DERIVED FACTOR INHIBITOR; PROTEIN BCL 2; PROTEIN BCL XL; PROTEINASE INHIBITOR; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; CELL SURVIVAL; DEGENERATIVE DISEASE; DRUG DESIGN; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVATION; HUMAN; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL PERMEABILITY; MOLECULAR MECHANICS; NERVE CELL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN SECRETION; PROTEIN TARGETING; REVIEW; TARGET CELL;

ANIMALS; APOPTOSIS; CASPASES; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; HUMANS; MITOCHONDRIA; MITOCHONDRIAL MEMBRANES; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS;

EID: 67649793306     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2009.03.007     Document Type: Review

References (81)

1. Acehan D., Jiang X., Morgan D.G., Heuser J.E., Wang X., and Akey C.W. Three-dimensional structure of the apoptosome: implications for assembly, procaspase-9 binding, and activation. Mol. Cell 9 (2002) 423-432
2. Adams J.M., and Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26 (2007) 1324-1337
3. Altar C.A., Boylan C.B., Jackson C., Hershenson S., Miller J., Wiegand S.J., Lindsay R.M., and Hyman C. Brain-derived neurotrophic factor augments rotational behavior and nigrostriatal dopamine turnover in vivo. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 11347-11351
4. Asoh S., Ohsawa I., Mori T., Katsura K., Hiraide T., Katayama Y., Kimura M., Ozaki D., Yamagata K., and Ohta S. Protection against ischemic brain injury by protein therapeutics. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 17107-17112
5. Badley A.D. In vitro and in vivo effects of HIV protease inhibitors on apoptosis. Cell Death Differ. 12 (2005) 924-931
6. Baines C.P., Kaiser R.A., Purcell N.H., Blair N.S., Osinska H., Hambleton M.A., Brunskill E.W., Sayen M.R., Gottlieb R.A., Dorn G.W., Robbins J., Molkentin J.D., Nakagawa T., Shimizu S., Watanabe T., Yamaguchi O., Otsu K., Yamagata H., Inohara H., Kubo T., and Tsujimoto Y. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 434 (2005) 658-662
7. Bao Q., and Shi Y. Apoptosome: a platform for the activation of initiator caspases. Cell Death Differ. 14 (2007) 56-65
8. Bao Q., Riedl S.J., and Shi Y. Structure of Apaf-1 in the auto-inhibited form: a critical role for ADP. Cell Cycle 4 (2005) 1001-1003
9. Barber B.R. Research news. Mouse News Lett. 45 (1971) 34-35
10. Bogaerts V., Theuns J., and van Broeckhoven C. Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria?. Genes Brain Behav. 7 (2008) 129-151 (Electronic publication 2007 Aug 3)
11. Boise L.H., Gonzalez-Garcia M., Postema C.E., Ding L., Lindsten T., Turka L.A., Mao X., Nunez G., and Thompson C.B. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74 (1993) 597-608
12. Borner C. The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol. Immunol. 39 (2003) 615-647
13. Bouchier-Hayes L., Lartigue L., and Newmeyer D.D. Mitochondria: pharmacological manipulation of cell death. J. Clin. Invest. 115 (2005) 2640-2647
14. Broekemeier K.M., Dempsey M.E., and Pfeiffer D.R. Cyclosporin A is a potent inhibitor of the inner membrane permeability transition in liver mitochondria. J. Biol. Chem. 264 (1989) 7826-7830
15. Cande C., Vahsen N., Kouranti I., Schmitt E., Daugas E., Spahr C., Luban J., Kroemer R.T., Giordanetto F., Garrido C., Penninger J.M., and Kroemer G. AIF and cyclophilin A cooperate in apoptosis-associated chromatinolysis. Oncogene 23 (2004) 1514-1521
16. Cao G., Pei W., Ge H., Liang Q., Luo Y., Sharp F.R., Lu A., Ran R., Graham S.H., and Chen J. In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. J. Neurosci. 22 (2002) 5423-5431
17. Chaum E. Retinal neuroprotection by growth factors: a mechanistic perspective. J. Cell. Biochem. 88 (2003) 57-75
18. Chu C.T., Zhu J.H., Cao G., Signore A., Wang S., and Chen J. Apoptosis inducing factor mediates caspase-independent 1-methyl-4-phenylpyridinium toxicity in dopaminergic cells. J. Neurochem. 94 (2005) 1685-1695
19. Culmsee C., Zhu C., Landshamer S., Becattini B., Wagner E., Pellecchia M., Blomgren K., and Plesnila N. Apoptosis-inducing factor triggered by poly(ADP-ribose) polymerase and Bid mediates neuronal cell death after oxygen-glucose deprivation and focal cerebral ischemia. J. Neurosci. 25 (2005) 10262-10272
20. Daugas E., Susin S.A., Zamzami N., Ferri K.F., Irinopoulou T., Larochette N., Prevost M.C., Leber B., Andrews D., Penninger J., and Kroemer G. Mitochondrio-nuclear translocation of AIF in apoptosis and necrosis. FASEB J. 14 (2000) 729-739
21. Deeks S.G., and Grant R.M. Sustained CD4 responses after virological failure of protease inhibitor-containing therapy. Antivir. Ther. 4 (1999) 7-11
22. Dietz G.P., Kilic E., and Bahr M. Inhibition of neuronal apoptosis in vitro and in vivo using TAT-mediated protein transduction. Mol. Cell. Neurosci. 21 (2002) 29-37
23. Estaquier J., Lelievre J.D., Petit F., Brunner T., Moutouh-De Parseval L., Richman D.D., Ameisen J.C., and Corbeil J. Effects of antiretroviral drugs on human immunodeficiency virus type 1-induced CD4(+) T-cell death. J. Virol. 76 (2002) 5966-5973
24. Ferri K.F., and Kroemer G. Mitochondria-the suicide organelles. Bioessays 23 (2001) 111-115
25. Frim D.M., Uhler T.A., Galpern W.R., Beal M.F., Breakefield X.O., and Isacson O. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 5104-5108
26. Gaedicke S., Firat-Geier E., Constantiniu O., Lucchiari-Hartz M., Freudenberg M., Galanos C., and Niedermann G. Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis. Cancer Res. 62 (2002) 6901-6908
27. Galluzzi L., Vitale I., Kepp O., Seror C., Hangen E., Perfettini J.L., Modjtahedi N., and Kroemer G. Methods to dissect mitochondrial membrane permeabilization in the course of apoptosis. Methods Enzymol. 442 (2008) 355-374
28. Garrido C., Galluzzi L., Brunet M., Puig P.E., Didelot C., and Kroemer G. Mechanisms of cytochrome c release from mitochondria. Cell Death Differ. 13 (2006) 1423-1433 (Electronic publication 2006 May 5)
29. Ghibelli L., Mengoni F., Lichtner M., Coppola S., De Nicola M., Bergamaschi A., Mastroianni C., and Vullo V. Anti-apoptotic effect of HIV protease inhibitors via direct inhibition of calpain. Biochem. Pharmacol. 66 (2003) 1505-1512
30. Gibson L., Holmgreen S.P., Huang D.C., Bernard O., Copeland N.G., Jenkins N.A., Sutherland G.R., Baker E., Adams J.M., and Cory S. bcl-w, a novel member of the bcl-2 family, promotes cell survival. Oncogene 13 (1996) 665-675
31. Green D.R., and Kroemer G. The pathophysiology of mitochondrial cell death. Science 305 (2004) 626-629
32. Green D.R., and Kroemer G. Pharmacological manipulation of cell death: clinical applications in sight?. J. Clin. Invest. 115 (2005) 2610-2617
33. Green D.R., and Reed J.C. Mitochondria and apoptosis. Science 281 (1998) 1309-1312
34. Harris B.S., Franz T., Ullrich S., Cook S., Bronson R.T., and Davisson M.T. Forebrain overgrowth (fog): a new mutation in the mouse affecting neural tube development. Teratology 55 (1997) 231-240
35. Hengartner M.O. The biochemistry of apoptosis. Nature 407 (2000) 770-776
36. Hisatomi T., Sakamoto T., Murata T., Yamanaka I., Oshima Y., Hata Y., Ishibashi T., Inomata H., Susin S.A., and Kroemer G. Relocalization of apoptosis-inducing factor in photoreceptor apoptosis induced by retinal detachment in vivo. Am. J. Pathol. 158 (2001) 1271-1278
37. Hisatomi T., Sakamoto T., Goto Y., Yamanaka I., Oshima Y., Hata Y., Ishibashi T., Inomata H., Susin S.A., and Kroemer G. Critical role of photoreceptor apoptosis in functional damage after retinal detachment. Curr. Eye Res. 24 (2002) 161-172
38. Hisatomi T., Sakamoto T., Sonoda K.H., Tsutsumi C., Qiao H., Enaida H., Yamanaka I., Kubota T., Ishibashi T., Kura S., Susin S.A., and Kroemer G. Clearance of apoptotic photoreceptors: elimination of apoptotic debris into the subretinal space and macrophage-mediated phagocytosis via phosphatidylserine receptor and integrin alphavbeta3. Am. J. Pathol. 162 (2003) 1869-1879
39. Hisatomi T., Nakazawa T., Noda K., Almulki L., Miyahara S., Nakao S., Ito Y., She H., Kohno R., Michaud N., Ishibashi T., Hafezi-Moghadam A., Badley A.D., Kroemer G., and Miller J.W. HIV protease inhibitors provide neuroprotection through inhibition of mitochondrial apoptosis in mice. J. Clin. Invest. 118 (2008) 2025-2038
40. Honarpour N., Gilbert S.L., Lahn B.T., Wang X., and Herz J. Apaf-1 deficiency and neural tube closure defects are found in fog mice. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 9683-9687
41. Hotchkiss R.S., McConnell K.W., Bullok K., Davis C.G., Chang K.C., Schwulst S.J., Dunne J.C., Dietz G.P., Bahr M., McDunn J.E., Karl I.E., Wagner T.H., Cobb J.P., Coopersmith C.M., and Piwnica-Worms D. TAT-BH4 and TAT-Bcl-xL peptides protect against sepsis-induced lymphocyte apoptosis in vivo. J. Immunol. 176 (2006) 5471-5477
42. Inohara N., Ding L., Chen S., and Nunez G. harakiri, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival-promoting proteins Bcl-2 and Bcl-X(L). EMBO J. 16 (1997) 1686-1694
43. Joza N., Oudit G.Y., Brown D., Benit P., Kassiri Z., Vahsen N., Benoit L., Patel M.M., Nowikovsky K., Vassault A., Backx P.H., Wada T., Kroemer G., Rustin P., and Penninger J.M. Muscle-specific loss of apoptosis-inducing factor leads to mitochondrial dysfunction, skeletal muscle atrophy, and dilated cardiomyopathy. Mol. Cell. Biol. 25 (2005) 10261-10272
44. Katoh I., Sato S., Fukunishi N., Yoshida H., Imai T., and Kurata S. Apaf-1-deficient fog mouse cell apoptosis involves hypo-polarization of the mitochondrial inner membrane, ATP depletion and citrate accumulation. Cell Res. 18 (2008) 1210-1219
45. Klein J.A., Longo-Guess C.M., Rossmann M.P., Seburn K.L., Hurd R.E., Frankel W.N., Bronson R.T., and Ackerman S.L. The harlequin mouse mutation downregulates apoptosis-inducing factor. Nature 419 (2002) 367-374
46. Kroemer G., and Reed J.C. Mitochondrial control of cell death. Nat. Med. 6 (2000) 513-519
47. Kroemer G., Zamzami N., and Susin S.A. Mitochondrial control of apoptosis. Immunol Today 18 (1997) 44-51
48. Kroemer G., Galluzzi L., and Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 87 (2007) 99-163
49. Lee T.H., Yang J.T., Ko Y.S., Kato H., Itoyama Y., and Kogure K. Influence of ischemic preconditioning on levels of nerve growth factor, brain-derived neurotrophic factor and their high-affinity receptors in hippocampus following forebrain ischemia. Brain Res. 1187 (2008) 1-11 (Electronic publication 2007 Oct 6)
50. Li L.Y., Luo X., and Wang X. Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 412 (2001) 95-99
51. Lorenzo H.K., Susin S.A., Penninger J., and Kroemer G. Apoptosis inducing factor (AIF): a phylogenetically old, caspase-independent effector of cell death. Cell Death Differ. 6 (1999) 516-524
52. Marzo I., Brenner C., Zamzami N., Susin S.A., Beutner G., Brdiczka D., Remy R., Xie Z.H., Reed J.C., and Kroemer G. The permeability transition pore complex: a target for apoptosis regulation by caspases and bcl-2-related proteins. J. Exp. Med. 187 (1998) 1261-1271
53. Marzo I., Susin S.A., Petit P.X., Ravagnan L., Brenner C., Larochette N., Zamzami N., and Kroemer G. Caspases disrupt mitochondrial membrane barrier function. FEBS Lett. 427 (1998) 198-202
54. Matarrese P., Gambardella L., Cassone A., Vella S., Cauda R., and Malorni W. Mitochondrial membrane hyperpolarization hijacks activated T lymphocytes toward the apoptotic-prone phenotype: homeostatic mechanisms of HIV protease inhibitors. J. Immunol. 170 (2003) 6006-6015
55. Mehta S.L., Manhas N., and Raghubir R. Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res. Rev. 54 (2007) 34-66 (Electronic publication 2007 Jan 12)
56. Murakami Y., Ikeda Y., Yonemitsu Y., Onimaru M., Nakagawa K., Kohno R., Miyazaki M., Hisatomi T., Nakamura M., Yabe T., Hasegawa M., Ishibashi T., and Sueishi K. Inhibition of nuclear translocation of apoptosis-inducing factor is an essential mechanism of the neuroprotective activity of pigment epithelium-derived factor in a rat model of retinal degeneration. Am. J. Pathol. 173 (2008) 1326-1338 (Electronic publication 2008 Oct 9)
57. Nakagawa T., Shimizu S., Watanabe T., Yamaguchi O., Otsu K., Yamagata H., Inohara H., Kubo T., and Tsujimoto Y. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 434 (2005) 652-658
58. Oltvai Z.N., Milliman C.L., and Korsmeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74 (1993) 609-619
59. Phenix B.N., Lum J.J., Nie Z., Sanchez-Dardon J., and Badley A.D. Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss. Blood 98 (2001) 1078-1085
60. Phenix B.N., Cooper C., Owen C., and Badley A.D. Modulation of apoptosis by HIV protease inhibitors. Apoptosis 7 (2002) 295-312
61. Riedl S.J., and Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat. Rev., Mol. Cell. Biol. 5 (2004) 897-907
62. Sanges D., Comitato A., Tammaro R., and Marigo V. Apoptosis in retinal degeneration involves cross-talk between apoptosis-inducing factor (AIF) and caspase-12 and is blocked by calpain inhibitors. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 17366-17371
63. Schwarze S.R., Ho A., Vocero-Akbani A., and Dowdy S.F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285 (1999) 1569-1572
64. Shimizu S., Konishi A., Kodama T., and Tsujimoto Y. BH4 domain of antiapoptotic Bcl-2 family members closes voltage-dependent anion channel and inhibits apoptotic mitochondrial changes and cell death. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 3100-3105
65. Slemmer J.E., Zhu C., Landshamer S., Trabold R., Grohm J., Ardeshiri A., Wagner E., Sweeney M.I., Blomgren K., Culmsee C., Weber J.T., and Plesnila N. Causal role of apoptosis-inducing factor for neuronal cell death following traumatic brain injury. Am. J. Pathol. 173 (2008) 1795-1805 (Electronic publication 2008 Nov 6)
66. Sloand E.M., Kumar P.N., Kim S., Chaudhuri A., Weichold F.F., and Young N.S. Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4(+) T cells and decreases their susceptibility to apoptosis in vitro and in vivo. Blood 94 (1999) 1021-1027
67. Staszewski S., Morales-Ramirez J., Tashima K.T., Rachlis A., Skiest D., Stanford J., Stryker R., Johnson P., Labriola D.F., Farina D., Manion D.J., and Ruiz N.M. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N. Engl. J. Med. 341 (1999) 1865-1873
68. Sugioka R., Shimizu S., Funatsu T., Tamagawa H., Sawa Y., Kawakami T., and Tsujimoto Y. BH4-domain peptide from Bcl-xL exerts anti-apoptotic activity in vivo. Oncogene 22 (2003) 8432-8440
69. Susin S.A., Zamzami N., Castedo M., Daugas E., Wang H.G., Geley S., Fassy F., Reed J.C., and Kroemer G. The central executioner of apoptosis: multiple connections between protease activation and mitochondria in Fas/APO-1/CD95- and ceramide-induced apoptosis. J. Exp. Med. 186 (1997) 25-37
70. Susin S.A., Lorenzo H.K., Zamzami N., Marzo I., Snow B.E., Brothers G.M., Mangion J., Jacotot E., Costantini P., Loeffler M., Larochette N., Goodlett D.R., Aebersold R., Siderovski D.P., Penninger J.M., and Kroemer G. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature 397 (1999) 441-446
71. Tsukahara T., Yonekawa Y., Tanaka K., Ohara O., Wantanabe S., Kimura T., Nishijima T., and Taniguchi T. The role of brain-derived neurotrophic factor in transient forebrain ischemia in the rat brain. Neurosurgery 34 (1994) 323-331 discussion 331
72. Vieira H.L., Haouzi D., El Hamel C., Jacotot E., Belzacq A.S., Brenner C., and Kroemer G. Permeabilization of the mitochondrial inner membrane during apoptosis: impact of the adenine nucleotide translocator. Cell Death Differ. 7 (2000) 1146-1154
73. Wan W., and DePetrillo P.B. Ritonavir protects hippocampal neurons against oxidative stress-induced apoptosis. Neurotoxicology 23 (2002) 301-306
74. Wang H., Shimoji M., Yu S.W., Dawson T.M., and Dawson V.L. Apoptosis inducing factor and PARP-mediated injury in the MPTP mouse model of Parkinson's disease. Ann. N.Y. Acad. Sci. 991 (2003) 132-139
75. Weaver J.G., Tarze A., Moffat T.C., Lebras M., Deniaud A., Brenner C., Bren G.D., Morin M.Y., Phenix B.N., Dong L., Jiang S.X., Sim V.L., Zurakowski B., Lallier J., Hardin H., Wettstein P., van Heeswijk R.P., Douen A., Kroemer R.T., Hou S.T., Bennett S.A., Lynch D.H., Kroemer G., and Badley A.D. Inhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitor. J. Clin. Invest. 115 (2005) 1828-1838
76. Yin W., Cao G., Johnnides M.J., Signore A.P., Luo Y., Hickey R.W., and Chen J. TAT-mediated delivery of Bcl-xL protein is neuroprotective against neonatal hypoxic-ischemic brain injury via inhibition of caspases and AIF. Neurobiol. Dis. 21 (2006) 358-371
77. Yoshida H., Kong Y.Y., Yoshida R., Elia A.J., Hakem A., Hakem R., Penninger J.M., and Mak T.W. Apaf1 is required for mitochondrial pathways of apoptosis and brain development. Cell 94 (1998) 739-750
78. Zamzami N., and Kroemer G. The mitochondrion in apoptosis: how Pandora's box opens. Nat. Rev., Mol. Cell. Biol. 2 (2001) 67-71
79. Zhao H., Yenari M.A., Cheng D., Sapolsky R.M., and Steinberg G.K. Bcl-2 overexpression protects against neuron loss within the ischemic margin following experimental stroke and inhibits cytochrome c translocation and caspase-3 activity. J. Neurochem. 85 (2003) 1026-1036
80. Zhao H., Yenari M.A., Cheng D., Barreto-Chang O.L., Sapolsky R.M., and Steinberg G.K. Bcl-2 transfection via herpes simplex virus blocks apoptosis-inducing factor translocation after focal ischemia in the rat. J. Cereb. Blood Flow Metab. 24 (2004) 681-692
81. Zhu C., Wang X., Huang Z., Qiu L., Xu F., Vahsen N., Nilsson M., Eriksson P.S., Hagberg H., Culmsee C., Plesnila N., Kroemer G., and Blomgren K. Apoptosis-inducing factor is a major contributor to neuronal loss induced by neonatal cerebral hypoxia-ischemia. Cell Death Differ. 14 (2007) 775-784 (Electronic publication 2006 Oct 13)